FWIW, from GNSC 10K -
ASTRAZENECA UK LIMITED
Effective November 29, 2001, we entered into a three-year agreement with AstraZeneca UK Limited, in which AstraZeneca gained limited access to our HAP-TM- Technology to investigate associations between our HAP-TM- Markers and disease susceptibility, in exchange for a specified, onetime payment. We granted AstraZeneca a perpetual exclusive license to use those HAP-TM- Markers that are shown to have a predictive association with a certain disease, for discovering, developing, manufacturing, marketing and selling of AstraZeneca drugs. We also granted AstraZeneca a perpetual, co-exclusive license, with us, to use the predictive HAP-TM- Markers for discovering, developing, manufacturing, marketing and selling prognostic products used in connection with the sale or prescription of AstraZeneca drugs. In exchange for these license grants, AstraZeneca granted us options, which expire in 2011, to obtain licenses under its intellectual property for making, using, marketing and selling prognostic and diagnostic products that detect these predictive HAP-TM- Markers. |
